Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Gram-Negative Infections | Unmet Need | HABP/VABP Gram-Negative Infections | US/EU | 2016

Login to access report north_east
Contact sales account_box

Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) are serious hospital-treated infections associated with high rates of multi-drug resistant (MDR) bacteria, including carbapenem-resistant organisms (CROs) (e.g., carbapenemase-producing Enterobacteriaceae and MDR A. baumannii and P. aeruginosa), as well as significant morbidity and mortality. Although several therapies in late-stage clinical development are active against these CROs, developers have faced difficulty in conducting HABP/VABP trials as a result of changes in and misalignment between the FDA’s and EMA’s clinical trial guidelines for this indication. Nonetheless, significant opportunity remains for antibiotic products with efficacy against drug-resistant HABP/VABP, including HABP/VABP due to CROs. Such therapies are poised to command premium prices in the GNI market.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east